Use of metformin in chronic kidney disease should continue to be based on common sense in the absence of an evidence base

Petrie, M.C. , Boyle, J.G. and McKay, G.A. (2015) Use of metformin in chronic kidney disease should continue to be based on common sense in the absence of an evidence base. Diabetic Medicine, 32(7), pp. 981-982. (doi:10.1111/dme.12709) (PMID:25645049)

Full text not currently available from Enlighten.

Abstract

We read with interest the paper by Adam et al. [1] which argues for less restrictive guidelines for using metformin in stable chronic renal failure. While the authors’ assumption that the use of metformin in patients with advanced chronic kidney disease (CKD) may be safe and offer similar cardiovascular disease and mortality benefit is reasonable, their enthusiasm for less restrictive guidance in patients with an estimated GFR of <30 ml/min should be tempered by the lack of good evidence of benefit for this group [2,3].

Item Type:Articles
Status:Published
Refereed:Yes
Glasgow Author(s) Enlighten ID:Boyle, Dr James and Petrie, Professor Mark and McKay, Dr Gerard
Authors: Petrie, M.C., Boyle, J.G., and McKay, G.A.
College/School:College of Medical Veterinary and Life Sciences > Institute of Cardiovascular and Medical Sciences
College of Medical Veterinary and Life Sciences > School of Medicine, Dentistry & Nursing
Journal Name:Diabetic Medicine
Publisher:Wiley-Blackwell Publishing Ltd.
ISSN:0742-3071
ISSN (Online):1464-5491

University Staff: Request a correction | Enlighten Editors: Update this record